We
present an overview of small molecule glucose-6-phosphate dehydrogenase
(G6PD) inhibitors that have potential for use in the treatment of
cancer, infectious diseases, and inflammation. Both steroidal and
nonsteroidal inhibitors have been identified with steroidal inhibitors
lacking target selectivity. The main scaffolds encountered in nonsteroidal
inhibitors are quinazolinones and benzothiazinones/benzothiazepinones.
Three molecules show promise for development as antiparasitic (25 and 29) and anti-inflammatory (32) agents. Regarding modality of inhibition (MOI), steroidal inhibitors
have been shown to be uncompetitive and reversible. Nonsteroidal small
molecules have exhibited all types of MOI. Strategies to boost the
discovery of small molecule G6PD inhibitors include exploration of
structure–activity relationships (SARs) for established inhibitors,
employment of high-throughput screening (HTS), and fragment-based
drug discovery (FBDD) for the identification of new hits. We discuss
the challenges and gaps associated with drug discovery efforts of
G6PD inhibitors from in silico, in vitro, and in cellulo to in vivo studies.